Autopsy report · NCT03436056
PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients
Cause of deathFunding or business
“funding pulled”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 4 months before it stopped.
- 2 participants enrolled.
- Results were posted on the registry 6 years 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Royal Marsden NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Conditions
- Metastatic Non-small-cell lunG Cancer
- Interventions
- Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#); Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#); Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose; Pembrolizumab
- Participants
- 2
- Sites
- 1
- Countries
- United Kingdom
Trials that died the same way
- Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
“Funding was pulled” - Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
“Funding Withdrawn” - Cannabinoids for Taxane Induced Peripheral Neuropathy
“Funding being sought” - Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
“funding was withdrawn” - Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
“Funding withdrawal”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.